Exxsun Corp (MNZO) Predicción del precio de las acciones

Manzo Pharmaceuticals, Inc. engages in the provision of pharmaceutical preparations services. The company is headquartered in North York, Ontario. The company went IPO on 2001-07-11. The firm also develops its lactose intolerance product, for which it holds an exclusive patent license. The firm's primary products are dietary supplements, probiotics and natural remedies. The firm's subsidiary, Manzo Pharmaceuticals LLC (Manzo), is an alternative healthcare company with patents for a probiotic remedy for lactose intolerance. The firm also owns other products, including a remedy for babies suffering from colic and/or digestive gas. Manzo's Lacto-Freedom probiotic is a probiotic that aids in the digestion of lactose-containing foods, designed specifically for people with lactose sensitivity.